Beone Medicines’ sonrotoclax (Beqalzi) gained U.S. FDA accelerated approval for relapsed or refractory mantle cell lymphoma after treatment with a BTK inhibitor. The approval marks the first BCL2-targeting therapy for this indication in the U.S., and Beone pointed to potential combination positioning with Brukinsa (zanubrutinib). The move brings another “BCL2 plus BTK” sequencing question into clinical practice, as clinicians weigh efficacy, durability, and tolerability in heavily pretreated patients. For Beone and category competitors, accelerated approval is a near-term revenue and trial catalyst—while confirmatory study expectations will shape longer-term value.